Niche Ophthalmic CRO EyeCRO specializes in preclinical ophthalmic studies using animal models, offering pharmacology/ efficacy, PK/tox, and eyedrop formulation development with proprietary MiDROPS technology to deliver high drug loads into the eye.

Proprietary Formulation MiDROPS is a patented platform enabling stable, safe topical eye formulations for lipophilic drugs, presenting a distinct value proposition to pharma companies seeking efficient ocular delivery solutions.

Strategic Partnerships Past collaborations with MPI Research and ongoing ARVO engagement indicate strong alignment with leading ophthalmic research networks, suggesting potential co-development, benchmarking, and multi-site study opportunities.

Growth Readiness With a lean team (11-50 employees) and revenue in the low to mid millions, EyeCRO appears poised for expandability through increased project throughput, selective service expansions, or scaled photopharmacology programs.

Market Opportunity Specialization in diverse ocular disease models (dry eye, AMD, retinopathy, glaucoma, uveitis, etc.) combined with preclinical pharmacology and formulation services positions EyeCRO to target mid-sized pharma and biotech firms seeking focused ophthalmic preclinical support.